Corporate Snapshot

TopoTarget A/S is developing novel pharmaceuticals for cancer and cancer-related indications, as well as on the identification of new indications for existing compounds. The Company's first internally developed product, Topotect, is in Phase III as an antidote for extravasation, a severe form of tissue damage resulting from an incorrect administration of cytotoxic anthracyclines or chemotherapy drugs. Pending approval, the Company could launch Topotect in winter 2005/2006. This product, based on the concept of deoxyribonucleic acid (DNA) damage control, would provide TopoTarget access to profitable, lower-risk markets. TopoTarget is also developing Topotect for the treatment of brain metastases, a life-threatening condition that affects approximately 60% of primary small cell lung cancer (SCLC) patients. Topotect recently entered Phase I/II clinical trials for this indication. Additionally, TopoTarget is heavily involved in the management of chromatins, the proteins responsible for the formation of DNA-containing chromosomes. The Company's expertise in this area has led to the development of PXD101, a Phase I anti-cancer histone deacetylase (HDAC) inhibitor that interferes with cell cycle arrest and angiogenesis, and has demonstrated anti-tumor activity in vivo. TopoTarget expects to employ this drug to target a variety of cancer indications, including multiple myeloma, malignant lymphoma, and ovarian, colorectal, and prostate cancer. TopoTarget also has a library of diverse HDAC inhibitors that have demonstrated efficacy in a variety of cancer and non-cancer indications.

* The Corporate Snapshot was last updated on January 26, 2005.

Latest Research

Executive
Informational
Overview

2005-01-26

Click to View

Stock Information (TOPO-NASDAQ OMX)